Pharmafile Logo

Almac group

Almac provides the most comprehensive range of services extending from research through pharmaceutical and clinical development to commercialisation of product. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30 years.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Company Details

Almac House, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, United Kingdom
+44 (0) 28 3833 2200

 Latest Content from PMHub 

Showcasing our multichannel capabilities in Berlin

Join Anthill for conferences in October to understand how to bring value to HCPs through multichannel communications

DAM and CMS: managing assets to maximise adoption and value

Senior Account Executive Dave Wood talks us through what DAM and CMS are, the role they play in the future of healthcare marketing, and how they can be best utilised...

Lucid launch new recruitment campaign to attract top talent in medical writing

We will offer talented writers an exclusive, tailor-made package to suit their individual needs and desires. We want you to define the framework of your Lucid Life contract – from...

Knowing your audience is key to successful medical education

Lucid Group understands that the goals of medical education are to disseminate best practice and advance patient outcomes. Our approach to meeting these goals centres on our appreciation of both...

How to enable each healthcare professional to fully understand your product

Read these three articles to understand how working at an individual level benefits all customers:

Alzheimer’s disease: reviewing the immediate treatment horizon

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

A stumble, but not a fall – what’s next for Opdivo?

Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

Meet Anthill at conferences in London

October, the month of multichannel pharma marketing in London. Meet us at DigiPharm and Multichannel Excellence Summit

Immuno-oncology; bringing patients closer to treatment

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?